Free tool
FAERS Monitor: Triesence
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 022048 or its brand name (Triesence, Triamcinolone Acetonide). Reports on generic versions are filed under their own applications.
Reports
24,723
Serious
13,254
54% of reports
Hospitalization
6,291
Death reported
3,176
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective3,844
- off label use2,908
- pruritus2,715
- rash2,561
- pain2,132
- fatigue2,036
- nausea1,946
- product use in unapproved indication1,748
- diarrhoea1,707
- vomiting1,703
- condition aggravated1,686
- headache1,626
- arthralgia1,549
- dizziness1,439
- infusion related reaction1,419
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 71 |
| 2005 | 58 |
| 2006 | 40 |
| 2007 | 80 |
| 2008 | 116 |
| 2009 | 130 |
| 2010 | 119 |
| 2011 | 178 |
| 2012 | 185 |
| 2013 | 209 |
| 2014 | 260 |
| 2015 | 477 |
| 2016 | 646 |
| 2017 | 816 |
| 2018 | 1,065 |
| 2019 | 1,229 |
| 2020 | 1,486 |
| 2021 | 1,795 |
| 2022 | 2,317 |
| 2023 | 2,750 |
| 2024 | 3,546 |
| 2025 | 3,872 |
| 2026 | 3,278 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,029,436 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| infusion related reactionSignal | 1,419 | 18.6 | 17.7 | 23,166 |
| pruritusSignal | 2,715 | 6.0 | 5.8 | 11,559 |
| product use in unapproved indicationSignal | 1,748 | 6.0 | 5.8 | 7,374 |
| rashSignal | 2,561 | 5.0 | 4.8 | 8,370 |
| condition aggravatedSignal | 1,686 | 4.7 | 4.5 | 5,014 |
| arthralgiaSignal | 1,549 | 3.2 | 3.0 | 2,347 |
| vomitingSignal | 1,703 | 3.1 | 3.0 | 2,450 |
| painSignal | 2,132 | 3.0 | 2.8 | 2,837 |
| off label useSignal | 2,908 | 2.8 | 2.7 | 3,581 |
| drug ineffectiveSignal | 3,844 | 2.5 | 2.4 | 3,629 |
| dizzinessSignal | 1,439 | 2.5 | 2.3 | 1,270 |
| diarrhoeaSignal | 1,707 | 2.3 | 2.2 | 1,223 |
| fatigueSignal | 2,036 | 2.2 | 2.1 | 1,426 |
| headacheSignal | 1,626 | 2.2 | 2.1 | 1,106 |
| nauseaSignal | 1,946 | 2.1 | 2.0 | 1,152 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.